WHO pre-qualification of an indigenous HPV vaccine marks a milestone for India's biotech ecosystem. Discuss its significance for public health in India and the Global South.

Cervavac is Serum Institute of India's quadrivalent HPV vaccine (types 6, 11, 16, 18). It has now entered WHO's list of prequalified vaccines [2], which makes it eligible for UN-agency procurement [1]. Its value now depends on how well it reaches people, at home and abroad.

Significance for India's biotech ecosystem

• Public–private–philanthropic model: DBT, BIRAC and the Gates Foundation worked with SII through Grand Challenges India [3]. This makes it a template for mission-mode innovation.
• Regulatory credibility: WHO PQ confirms that the vaccine meets global quality standards. This strengthens India's image as the "pharmacy of the world" [2].

Significance for public health in India

• Disease burden: About 1.25 lakh cases and 75,000+ deaths occur each year, and 83% of invasive cases are linked to HPV 16/18. Both types are covered by Cervavac [3].
• Gender-neutral potential: It is indicated for girls and boys aged 9–26, which builds herd protection [1].
• Self-reliance: India's free drive, launched in February 2026, targets 1.15 crore girls aged 14 each year but uses imported Gardasil [4]. A proven domestic vaccine would cut costs and reduce dependence on one supplier.

Significance for the Global South

• Easing supply: Global HPV vaccine shortages have persisted since 2018 [5]. Another prequalified supplier helps Africa and Asia.
• Closing the coverage gap: Only 27% of girls aged 9–14 worldwide received a dose in 2023, against WHO's 90% target [5].
• Vaccine diplomacy: Supplies through UNICEF and Gavi raise India's standing in South–South health cooperation [1].

Limitations to address

• Single-dose evidence: WHO already backs single-dose schedules, and China's Cecolin is cleared for one dose [5]. Cervavac's chances in tenders and in the national drive depend on similar evidence.
• Screening still matters: Vaccinating adolescents does not protect women who are adults today.

In sum, PQ turns an Indian innovation into a global public good. Quickly producing single-dose evidence, switching the national drive to Cervavac, and keeping screening going alongside vaccination can bring India closer to WHO's cervical-cancer elimination goal and SDG 3.4.